4 Dental Supplies Stocks Likely to Gain Amid Rising Tariff Risks

The U.S. dental supplies industry faces near-term challenges through 2025 due to rising tariffs, particularly on Chinese imports, which are increasing costs and disrupting supply chains, coupled with weakened demand for elective procedures. Despite these headwinds, the global dental industry is projected for significant long-term growth, expected to reach $610.4 billion by 2032 at a 4.5% CAGR, driven by an aging population, technological advancements, and increased preventive care. Key industry participants such as West Pharmaceutical Services (WST), McKesson (MCK), Cardinal Health (CAH), and The Cooper Companies (COO) are highlighted as well-positioned to deliver favorable performance amid the broader market dynamics.

Analysis

The U.S. Medical Dental Supplies industry is navigating a challenging near-term environment characterized by significant headwinds. Ongoing U.S. tariffs, particularly on Chinese goods, are projected to persist through 2025, elevating costs for critical imported items and creating supply chain disruptions. This is compounded by a notable weakness in domestic demand for elective procedures, specifically impacting sales of CAD/CAM, imaging, and restorative products. This pressure is reflected in the industry's market performance, which has declined 0.4% over the past year against a 20.5% gain in the S&P 500, and its valuation, which at a forward P/E of 16.05X, is at a five-year low and below both its sector and the broader market. Despite these short-term issues, the long-term outlook remains robust, underpinned by a projected global market CAGR of 4.5% through 2032, driven by powerful secular trends including an aging population, technological innovation, and rising awareness of preventive care. The companies highlighted—West Pharmaceutical (WST), McKesson (MCK), Cardinal Health (CAH), and Cooper Companies (COO)—are diversified players demonstrating resilience. WST raised its 2025 revenue and EPS guidance, though it incorporates a $15-$20 million negative tariff impact. MCK and CAH are leveraging strength in pharmaceutical distribution, particularly specialty drugs, with MCK raising its fiscal 2026 EPS guidance and expecting 13% earnings growth in fiscal 2025. COO is demonstrating steady performance with analysts forecasting 10% earnings growth for 2025, despite some FX headwinds.

Key Decisions for Investors

• Investors should weigh the sector's depressed valuation, with a forward P/E at a five-year low of 16.05X, against near-term headwinds from tariffs and weak elective procedure demand, viewing the current environment as a potential entry point for long-term exposure to demographic and technological growth.
• Consider prioritizing investment in the highlighted diversified healthcare companies like McKesson (MCK) and West Pharmaceutical (WST), which exhibit strong growth drivers outside of the core dental market, such as specialty pharma distribution and proprietary biologics components, providing a buffer against dental-specific softness.
• Closely monitor U.S. trade policy developments and company-specific supply chain adjustments, as any relief from tariffs, which range from 10% to over 50%, would be a primary catalyst for margin improvement and a potential re-rating of the sector.